AZADYNE
Azadyne’s novel approach to treating autoimmune disease focuses on an unexplored pathway in the body and is based on research conducted at Trinity by Associate Professor in Biochemistry Vincent Kelly, Professor of Synthetic Chemistry Professor Stephen Connon and assistant Professor in Chemistry John Michael Southern.
AZADYNE
Social Links:
Industry:
Health Care
Founded:
2016-01-01
Address:
Dublin, Dublin, Ireland
Country:
Ireland
Website Url:
http://www.azadyne.com
Total Employee:
1+
Status:
Active
Total Funding:
1.75 M EUR
Technology used in webpage:
Pound Sterling Gravity Forms
Similar Organizations
Cabaletta Bio
Cabaletta Bio has adapted clinically-validated and FDA-approved CAR T cell technology to target B cell-mediated autoimmune diseases.
D2M Biotherapeutics
D2M Biotherapeutics focuses on the development of novel immunotherapeutics.
Elgia Therapeutics
Elgia Therapeutics is a biopharmaceutical company.
Kytopen
Kytopen developer of a cell therapy platform for non-viral delivery of molecules into hard-to-transfect immune cells.
METiS Therapeutics
METiS Therapeutics uses integrated drug discovery to develop medicines in a variety of illness areas.
Recensa Therapeutics
Recensa Therapeutics, Inc. has a new approach to treating psoriasis: targeting oxidative stress.
STipe Therapeutics
STipe Therapeutics focuses on harnessing the innate immune system to battle cancer.
Current Employees Featured
Founder
Investors List
Renaissance Capital Partners
Renaissance Capital Partners investment in Venture Round - Azadyne
NCL Technology Ventures
NCL Technology Ventures investment in Seed Round - Azadyne
Renaissance Capital Partners
Renaissance Capital Partners investment in Seed Round - Azadyne
Official Site Inspections
http://www.azadyne.com Semrush global rank: 11.54 M Semrush visits lastest month: 156
- Host name: 141.193.213.11
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Azadyne"
New approach to treating autoimmune disease - Azadyne
Azadyne Azadyne are a preclinical biotech company with a new approach to treating autoimmune disease. We have identified a new target within the body and a previously undrugged pathway. …See details»
About Us - Azadyne
Azadyne’s groundbreaking work in RNA modification has been supported by investment syndicates led by NCL & Kent Life Sciences and private equity group 24 Haymarket. Azadyne is a virtual company with a team of experienced …See details»
Azadyne - Crunchbase Company Profile & Funding
Azadyne’s novel approach to treating autoimmune disease focuses on an unexplored pathway in the body and is based on research conducted at Trinity by Associate Professor in …See details»
Azadyne Ltd - LinkedIn
Azadyne Ltd | 234 followers on LinkedIn. Treating Autoimmune disease. | We are a pharma R&D company dedicated to delivering improved medicines for patients with autoimmune disease, including ...See details»
Azadyne 2025 Company Profile: Valuation, Funding & Investors
Azadyne General Information Description. Developer of novel RNA modification technologies designed to treat autoimmune diseases by increasing treg cell levels. The company aims to …See details»
Azadyne - Headquarter Location, Corporate Office Address and …
Azadyne is Biotechnology business from United Kingdom that founded in 2018 (7 years old in 2025), Azadyne business is focusing on Developer. Where is Azadyne headquarter and …See details»
Azadyne Company Profile - Office Locations, Competitors ... - Craft
Azadyne is a pharmaceutical research and development company. It is engaged in discovering medicines for patients with autoimmune disease, including multiple sclerosis.See details»
Azadyne Announce Funding Round
Azadyne’s proprietary and innovative approach to autoimmune disease via the tRNA guanine transglycosylase (TGT) enzyme pathway has shown striking efficacy in pre-clinical studies …See details»
Azadyne - VentureRadar
Azadyne was founded based on published research findings, showing that queuine mimetics can drastically reverse the clinical disease process (i.e. paralysis and autoimmunity) associated …See details»
Azadyne - Funding, Financials, Valuation & Investors - Crunchbase
Azadyne is a new approach to the treatment of autoimmune diseases. New. Resources. Advanced Search. Start Free Trial . Talk With Sales. Pricing. Log In. ... How much funding has …See details»
AZADYNE LTD Company Profile | LONDON, United Kingdom
Find company research, competitor information, contact details & financial data for AZADYNE LTD of LONDON. Get the latest business insights from Dun & Bradstreet. D&B Business …See details»
Azadyne – Funding, Valuation, Investors, News
Sep 30, 2022 We are a pharma R&D company dedicated to delivering improved medicines for patients with autoimmune disease, including Multiple Sclerosis. AZADYNE originated from …See details»
Azadyne - Products, Competitors, Financials, Employees, …
Azadyne operates as a preclinical biotechnology company focused on the healthcare sector, specifically in the field of autoimmune disease treatment. The company's main service …See details»
Azadyne - Contacts, Employees, Board Members, Advisors & Alumni
Azadyne is a new approach to the treatment of autoimmune diseases. AI Content may contain mistakes and is not legal, financial or investment advice.See details»
Science & Pipeline - Azadyne
Azadyne’s research has focused on the exploitation of the queuine tRNA ribosyltransferase (QTRT) enzyme pathway (also known as TGT), characterised by the founders (Boland et al., …See details»
Azadyne - EU-Startups
Azadyne is a biotech spin-out company from Trinity College Dublin founded by Professors Stephen Connon, Vincent Kelly, Mike Southern and CEO, Dr. Jason Rutt, ex head of UK …See details»
Contact - Azadyne
Azadyne is always keen to discuss its science. To learn more about the work we are doing, or to discuss ways we can work together, please get in contact using the form below. Name …See details»
Azadyne, a biotech startup targeting autoimmune disease wins …
Cambridge, UK, November 2nd, 2022: o2h discovery is pleased to announce Azadyne as a winner of the o2h Kickstarter competition.Azadyne’s approach has shown striking efficacy in …See details»
Azadyne, a biotech startup targeting autoimmune disease wins …
O2h discovery is pleased to announce Azadyne as a winner of the o2h Kickstarter competition. Azadyne’s approach has shown striking efficacy in pre-clinical studies via the tRNA guanine …See details»
News - Azadyne
Read More about Azadyne speaking at FASEB RNA conference. March 27, 2019 Azadyne Announce Funding Round. Azadyne, which is developing a new approach to the treatment of …See details»